Do you (or the companies) have any numbers to estimate the size of the Single-Cell and Spatial Opportunity ? If that is the bull case what is the current market size (tam)?
10x Genomics claims they have a serviceable addressable market of over 13B annually, but its revenue came in at ~610mm last year and it's run into growth headwinds as of late (A portion of that revenue is from its Xenium In Situ analysis instrument/consumables, something Ilmn doesn't offer).
I think the real question over time is whether single-cell/spatial can start having significant applications on the clinical side of things. To be really excited about the opportunity you need to think single-cell/spatial usage is going to grow at a rate that more than compensates for drops in price, and so the TAM is actually larger than it currently sits at.
Thank you.
Do you (or the companies) have any numbers to estimate the size of the Single-Cell and Spatial Opportunity ? If that is the bull case what is the current market size (tam)?
10x Genomics claims they have a serviceable addressable market of over 13B annually, but its revenue came in at ~610mm last year and it's run into growth headwinds as of late (A portion of that revenue is from its Xenium In Situ analysis instrument/consumables, something Ilmn doesn't offer).
I think the real question over time is whether single-cell/spatial can start having significant applications on the clinical side of things. To be really excited about the opportunity you need to think single-cell/spatial usage is going to grow at a rate that more than compensates for drops in price, and so the TAM is actually larger than it currently sits at.
Thank you. I appreciate sharing your thoughts.